Zacks: Athenex Inc (ATNX) Given Consensus Rating of “Buy” by Analysts
Shares of Athenex Inc (NASDAQ:ATNX) have been assigned a consensus broker rating score of 2.00 (Buy) from the three brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Athenex’s rating score has declined by 33.3% from three months ago as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a 1-year consensus price objective of $25.73 for the company, according to Zacks. Zacks has also given Athenex an industry rank of 109 out of 265 based on the ratings given to its competitors.
Several equities analysts recently commented on the stock. J P Morgan Chase & Co assumed coverage on shares of Athenex in a research report on Wednesday, October 18th. They set a “neutral” rating and a $22.20 price target for the company. Laidlaw assumed coverage on shares of Athenex in a research report on Tuesday, September 19th. They set a “buy” rating and a $36.00 price target for the company. Credit Suisse Group assumed coverage on shares of Athenex in a research report on Monday, September 18th. They set an “outperform” rating and a $25.00 price target for the company. Finally, Royal Bank of Canada assumed coverage on shares of Athenex in a research report on Thursday, September 14th. They set an “outperform” rating and a $35.00 price target for the company.
Athenex (NASDAQ ATNX) opened at $16.83 on Friday. Athenex has a one year low of $11.21 and a one year high of $20.79.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.